# Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability

> **NCT01928381** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 150 (actual)

## Conditions studied

- Diabetic Neuropathy, Painful; Diabetic Neuropathies

## Interventions

- **DRUG:** AZD5213 + pregabalin
- **DRUG:** Placebo
- **DRUG:** pregabalin capsules

## Key facts

- **NCT ID:** NCT01928381
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2016-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01928381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01928381, "Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01928381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*